Blueprint Medicines Corporation (0HOJ.L)
USD 82.77
(2.95%)
USD 82.77
(2.95%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 249.38 Million USD | 22.22% |
| 2022 | 204.03 Million USD | 13.3% |
| 2021 | 180.08 Million USD | -77.31% |
| 2020 | 793.73 Million USD | 1093.37% |
| 2019 | 66.51 Million USD | 49.39% |
| 2018 | 44.52 Million USD | 107.79% |
| 2017 | 21.42 Million USD | -22.85% |
| 2016 | 27.77 Million USD | 143.61% |
| 2015 | 11.4 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 128.18 Million USD | -7.22% |
| 2024 Q1 | 96.11 Million USD | 33.57% |
| 2024 Q2 | 138.15 Million USD | 43.74% |
| 2023 Q4 | 71.95 Million USD | 27.21% |
| 2023 FY | 249.38 Million USD | 22.22% |
| 2023 Q1 | 63.28 Million USD | 63.19% |
| 2023 Q2 | 57.57 Million USD | -9.03% |
| 2023 Q3 | 56.56 Million USD | -1.74% |
| 2022 Q1 | 62.73 Million USD | -41.38% |
| 2022 FY | 204.03 Million USD | 13.3% |
| 2022 Q2 | 36.54 Million USD | -41.74% |
| 2022 Q4 | 38.78 Million USD | -41.22% |
| 2022 Q3 | 65.97 Million USD | 80.53% |
| 2021 Q4 | 107.02 Million USD | 342.46% |
| 2021 Q1 | 21.57 Million USD | -36.74% |
| 2021 Q2 | 27.29 Million USD | 26.51% |
| 2021 Q3 | 24.18 Million USD | -11.38% |
| 2021 FY | 180.08 Million USD | -77.31% |
| 2020 FY | 793.73 Million USD | 1093.37% |
| 2020 Q4 | 34.1 Million USD | -95.42% |
| 2020 Q3 | 745.11 Million USD | 8831.06% |
| 2020 Q2 | 8.34 Million USD | 35.28% |
| 2020 Q1 | 6.16 Million USD | -88.03% |
| 2019 Q2 | 5.11 Million USD | 600.0% |
| 2019 Q3 | 9.13 Million USD | 78.85% |
| 2019 Q4 | 51.53 Million USD | 463.88% |
| 2019 FY | 66.51 Million USD | 49.39% |
| 2019 Q1 | 730 Thousand USD | -29.33% |
| 2018 Q1 | 954 Thousand USD | -41.4% |
| 2018 Q2 | 41.43 Million USD | 4243.71% |
| 2018 Q3 | 1.09 Million USD | -97.36% |
| 2018 Q4 | 1.03 Million USD | -5.66% |
| 2018 FY | 44.52 Million USD | 107.79% |
| 2017 Q3 | 8.06 Million USD | 36.98% |
| 2017 Q2 | 5.89 Million USD | 0.86% |
| 2017 Q1 | 5.84 Million USD | -24.07% |
| 2017 FY | 21.42 Million USD | -22.85% |
| 2017 Q4 | 1.62 Million USD | -79.82% |
| 2016 Q4 | 7.69 Million USD | 24.85% |
| 2016 Q3 | 6.16 Million USD | -12.81% |
| 2016 Q2 | 7.06 Million USD | 3.05% |
| 2016 FY | 27.77 Million USD | 143.61% |
| 2016 Q1 | 6.85 Million USD | 47.92% |
| 2015 Q3 | 3.42 Million USD | 27.5% |
| 2015 FY | 11.4 Million USD | 0.0% |
| 2015 Q2 | 2.68 Million USD | 312.12% |
| 2015 Q4 | 4.63 Million USD | 35.29% |
| 2015 Q1 | 652 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.418% |
| Dynavax Technologies Corporation | 232.28 Million USD | -7.36% |
| Illumina, Inc. | 4.5 Billion USD | 94.463% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 98.336% |
| Biogen Inc. | 9.83 Billion USD | 97.465% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -20873.928% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 93.417% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 79.943% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 58.951% |
| Waters Corporation | 2.95 Billion USD | 91.565% |
| Perrigo Company plc | 4.65 Billion USD | 94.643% |
| uniQure N.V. | 15.84 Million USD | -1474.071% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -829.724% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 37.554% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -2808.9% |
| bluebird bio, Inc. | 29.49 Million USD | -745.442% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -1089.336% |
| Imunon, Inc. | - USD | -Infinity% |
| Myriad Genetics, Inc. | 678.4 Million USD | 63.24% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 86.785% |
| Nektar Therapeutics | 90.12 Million USD | -176.714% |
| Editas Medicine, Inc. | 78.12 Million USD | -219.215% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.831% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -96.294% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 89.692% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -41.507% |
| Evolus, Inc. | 202.08 Million USD | -23.404% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -698.042% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 98.099% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -114.366% |
| FibroGen, Inc. | 147.75 Million USD | -68.783% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 96.35% |
| OPKO Health, Inc. | 863.49 Million USD | 71.12% |
| Homology Medicines, Inc. | -6.65 Million USD | 3849.511% |
| Geron Corporation | 237 Thousand USD | -105123.629% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 86.36% |
| Exelixis, Inc. | 1.83 Billion USD | 86.374% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -587.471% |
| Zoetis Inc. | 8.54 Billion USD | 97.081% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 7.842% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -7025.143% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 97.473% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 68.339% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 48.302% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 69.927% |
| Insmed Incorporated | 305.2 Million USD | 18.292% |
| TG Therapeutics, Inc. | 233.66 Million USD | -6.727% |
| Incyte Corporation | 3.69 Billion USD | 93.252% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 76.234% |